Philips oxygen sensor accuracy put to the test in 113 adults
NCT ID NCT06484452
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study tested whether Philips non-invasive SpO2 sensors can accurately measure blood oxygen levels compared to the standard method of drawing blood and analyzing it in a lab. 113 healthy adults aged 18-50 took part. The goal was to see how well the sensors work across oxygen levels from 70% to 100%.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could confirm that Philips SpO2 sensors are accurate enough for reliable oxygen monitoring without needles.
- What could go wrong
- This is a small, completed validation study in healthy adults aged 18-50, so results may not apply to older or sicker patients. The sensors were tested in a controlled setting, not real-world use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
113 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population for this protocol will include a minimum of 96 to a maximum of 120 healthy, competent adult male and female participants of any race and ranging in pigmentation from light to dark. Participants will be non-smoking (or have refrained from smoking for 2 days) and between the ages of 18-50 years old.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant must have the ability to understand and provide written informed consent * Participant is adult between 18-50 years of age * Participant must be willing and able to comply with study procedures and duration * Participant is a non-smoker or who has not smoked within 2 days prior to the study. Exclusion Criteria: * Participant is considered as being morbidly obese (defined as BMI \>39.5) * Participants with compromised circulation (i.e., Raynaud's Syndrome), injury, or physical malformation of fingers, toes, hands, ears, nose, forehead/skull, or other sensor sites which would limit the ability to test sites needed for the study. Tattoo (e.g. permanent, Henna) or artificial dyes (including spray tan, pigmented tanning lotion) in the optical path which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow participants to participate if the condition is noted and would not affect the particular sites utilized.) * Females who are pregnant, who are trying to get pregnant, (confirmed by positive urine pregnancy test unless the participant is known to be not of child-bearing potential) * Participants who have smoked in the last 2 days or participants who have refrained, for at least 48 hours, with COHb levels \>3% as assessed with a Masimo Radical 7 (Rainbow) * Participants with known respiratory conditions such as: (self-reported) * uncontrolled / severe asthma, * flu, * pneumonia / bronchitis, * shortness of breath / respiratory distress, * unresolved respiratory or lung surgery, * emphysema, COPD, lung disease, * Recent COVID (last 2 months) * Participants with self-reported heart or cardiovascular conditions such as: (self-reported, except for blood pressure and ECG review) * high blood pressure: systolic \>140 mmHg or diastolic \>90 mmHg on 3 consecutive readings (reviewed during health screen), * have had cardiovascular surgery, except successful minor surgery without clinical symptoms (i.e., PFO, PDA), * chest pain (angina), * heart rhythms other than a normal sinus rhythm or with respiratory sinus arrhythmia (reviewed during health screen), * previous heart attack, * blocked artery, * unexplained shortness of breath, * congestive heart failure (CHF), * history of stroke, * transient ischemic attack, * carotid artery disease, * myocardial ischemia, * myocardial infarction, * cardiomyopathy, * implantable active medical device such as pacemaker or automatic defibrillator * Participants with self-reported health conditions as identified in the Health Assessment Form * diabetes, * uncontrolled thyroid disease, * kidney disease / chronic renal impairment, * history of seizures (except childhood febrile seizures), * epilepsy, * history of unexplained syncope, * recent history of frequent migraine headaches, * recent symptomatic head injury (within the last 2 months), * Cancer requiring chemotherapy, radiation, or current treatment * Participants with known clotting disorders (self-reported) * history of bleeding disorders or personal history of prolonged bleeding from injury, * history of blood clots, * hemophilia, * current use of blood thinner: prescription or daily use of aspirin, * Sickle Cell Trait or Disease * Participants with self-reported dermatological conditions at sensor application sites * Severe dermatitis, * Hyperkeratosis, * Nail fungus * Participants with severe contact allergies to standard adhesives, latex, silicone or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors (self-reported) * Participants with severe allergies to iodine (only applicable if iodine is used) * Participants with severe allergies to lidocaine (or similar pharmacological agents, e.g. Novocaine), * Failure of the Perfusion Index Ulnar/Ulnar+Radial Ratio test (Ratio \<0.4) * Unwillingness or inability to remove colored nail polish or artificial nails from test digits * Participants with stretched or dilated piercings at the application site of ear sensors. (Applicable for test groups with M1194A and EX-Alar on ear only.) * Participant received intravascular dye within the past 48 hours (e.g. Indocyanine green, methylene blue, dyes used in cardiac output monitoring) * Surgical hardware in pathway of Device Under Test * Other known health condition, should be considered upon disclosure in health assessment form
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulse oximetry are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Element Materials Technology
Louisville, Colorado, 80027, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.